This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ResApp Health Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.0%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-AU$0.0083
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if RAP's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if RAP's dividend payments have been increasing.

Dividendenrendite im Vergleich zum Markt

ResApp Health Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von RAP im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (RAP)	n/a
Untere 25 % des Marktes (AU)	2.7%
Markt Top 25 % (AU)	6.5%
Branchendurchschnitt (Healthcare Services)	1.0%
Analystenprognose in 3 Jahren (RAP)	0%

Bemerkenswerte Dividende: Unable to evaluate RAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate RAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as RAP has not reported any payouts.

This company listing is no longer active

ResApp Health Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited (ASX:RAP).

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.009 loss in FY 2021)

ResApp Health Limited to Report Q4, 2022 Results on Jul 27, 2022

ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx

ResApp Health Limited Announces Results from Data Confirmation Study

No independent directors

No independent directors

ResApp Health Limited to Report Q3, 2022 Results on Apr 26, 2022

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ResApp Health Limited Completes Recruitment in its U.S. Covid-19 Clinical Study

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

ResApp Receives Regulatory Approvals for Cough Counter

ResApp Health Limited Completes COVID-19 Study Recruitment in India

ResApp Health Limited Receives Advanced and Overseas R&D Finding

ResApp Health Limited Receives Regulatory Approval in Indonesia

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Medgate Extends European ResAppDx Trial

Forecast breakeven moved forward to 2021

ResApp Health Limited Reports Recruited the First Participant in Its US-Based Clinical Study to Explore the Relationship Between Cough and SARS-Cov2 Infection

Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation

ResApp to Progress Clinical Study to Develop Covid-19 Smartphone-Based Screening Test

Medgate AG Commences ResApp Health Limited 's European ResAppDx Trial

Resapp Health Limited Achieves CE Mark for Wearable Device

ResApp Health Limited Provides an Update on its Two-Year, Non-Exclusive Software Licencing Agreement with Workplace Medicine Australia Ltd

ResApp Health Limited Announces Resignation of Stephen Hewitt-Dutton as Joint Company Secretary

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited Strengthens Patent Position in Europe

ResApp Health Limited to Report Q2, 2021 Results on Jan 29, 2021

Resapp Health Limited Appoints Mike Connell as Vice President, Commercial

ResApp Health Limited Launches SleepCheck

Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth

ResApp Health Limited Releases Version 2.3 of its ResAppDx Smartphone Application

ResApp Health Limited Appoints Stephen Hewitt-Dutton as Joint Company Secretary

ResApp Health Limited Signs Non-Exclusive, Two-Year Software Licensing Agreement with Workplace Medicine Australia Ltd

Medgate to Pilot ResAppDx for Telehealth Across Europe

ResApp Health Limited to Report Q1, 2021 Results on Oct 30, 2020

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited to Report Q4, 2020 Results on Jul 29, 2020

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen